Kornimate/medical-research-clean huggingface dataset:
mixed-methods evaluation of short-, medium-, and long-term outcomes following hip treatment

Conditions: Hip Dysplasia; Legg-Calvâe-Perthes Disease; Avascular Necrosis of Hip

Summary: this study, titled "mixed-methods evaluation of short-, medium-, and long-term outcomes following hip treatment," aims to assess the long-term effectiveness of treatments for pediatric hip conditions, including hip dysplasia, legg-calve-perthes disease, scfe, and avascular necrosis.

conducted at mayo clinic, the study combines retrospective chart reviews and prospective follow-up to gather data on clinical outcomes, radiographic measures, and patient-reported outcomes (pros) like functional status, pain, and quality of life. the retrospective component analyzes records from 1975 to 2024, while the prospective component includes follow-up surveys using validated pro measures (e.g., hoos, sf-12, vas). this study seeks to identify recurrence rates and complications associated with hip treatments, providing insights to improve future care standards for pediatric hip conditions. data will be securely stored, with confidentiality maintained throughout.

Eligibility criteria:
inclusion criteria: * patients over the age of 18 seen for a concern of hip pathology at mayo between 1975 and 2024 * patients over 18 who can be contacted for follow-up and are willing to participate. exclusion criteria: * patients presenting over age 18 for hip dysplasia * patients who are unwilling to complete follow up surveys.
clinical validation of a cardiovascular autonomic nervous function multi-parameter evaluation system

Conditions: Cardiovascular Autonomic Neuropathy

Summary: this is a open-label, randomized, paired design, multicenter study of the cardiovascular autonomic nervous function multi-parameter evaluation system (r6000) for evaluating cardiovascular autonomic neuropathy. r6000 is novel intellectual diagnostic device for cardiovascular autonomic reflex tests and heart rate variability analysis. a total of 85 subjects will be enrolled in trial ⅰ and 150 subjects will be enrolled in trial ⅱ. in trial ⅰ, subjects will be randomized to two groups, one of which will receive test by the tested device first and the other one will be tested by conventional blood pressure kit. the primary objective of this clinical trial is to evaluate the effectiveness of the cardiovascular autonomic nervous function multi-parameter evaluation system. the secondary objective is to evaluate the safety of the cardiovascular autonomic testing system and stability.

trial i tested device: cardiovascular autonomic nervous function multi-parameter evaluation system (r6000). control: conventional blood pressure kit. goal: to assess the consistency between the tested device and the conventional method in measuring blood pressure. trial iia tested device: cardiovascular autonomic nervous function multi-parameter evaluation system (r6000). control: ambulatory holter station. goal: to assess the consistency between the tested device and the conventional devices in measuring heart rate variability (hrv). trial iib tested device: cardiovascular autonomic nervous function multi-parameter evaluation system (r6000). control: manual method with digital ecg machine, stethoscope and sphygmomanometer. goal: to assess the consistency between the tested device and the manual method in determining cardiovascular autonomic neuropathy (can).

Eligibility criteria:
inclusion criteria: * individuals aged 18 or over, regardless of gender * voluntary membership to participate in the study and signing the informed consent form. exclusion criteria: * for part i: • unable to cooperate with the examination. * for part ii: * ophthalmic examination within the past 1 month showed proliferative retinopathy, retinal detachment, fundus hemorrhage or presence of known history of illness described above; * known history of glaucoma or ophthalmic examination within the past 1 month suggests glaucoma; * poor control of hypertension (sedentary systolic blood pressure ≥ 160mmhg or diastolic blood pressure ≥100mmhg); * known history of arrhythmia (except occasional premature beats), history of acute coronary syndrome within three months before signing the informed consent form; * in a state of stress such as infection and surgery; be in the acute or unstable phase of any disease; * pregnant women; * unable to cooperate with the examination.
transcutaneous nerve stimulation for post-operative acute and chronic pain

Conditions: Postoperative Pain; Hip Fracture

Summary: aim of the study to assess the efficacy of two modes of transcutaneous electrical nerve stimulation (tens) on relief of postoperative acute pain after hip fracture surgery.

the patients underwent undergo fractured hip surgery will be distributed into three groups with respect to the mode of postoperative analgesia applied: group i (control): pca only; group ii: pca plus lumbar plexus \& sciatic nerve tens (ls-tens); group iii: pca plus surgical wound tens (sw-tens). tens will be applied every 2 hours for 30-40 minutes during 48 hours postoperatively. visual analogue score (vas), ramsey sedation scores, frequencies of pca demand and counts of pca delivery, as well as total analgesic consumption will be noted and compared between groups at various time intervals. visual analog scale (vas) will be applied at 2 months postoperatively vas and mcgill pain questionnaire will be applied at the 6th and 24th months of the surgery to assess acute and chronic pain in the study population and the differences among groups.

Eligibility criteria:
inclusion criteria: adult patients will be scheduled for surgery due to hip fracture in mustafa kemal university hospital will be included in the study. exclusion criteria: patients with a history of opioid analgesic abuse, or sensitivity to opioids, and those with clinically significant systemic (cardiovascular, pulmonary, hepatic, renal, neurologic etc.) diseases, will be excluded.

Keywords: percutaneous electric nerve stimulation lumbosacral plexus surgical wound postoperative analgesia transcutaneous electrical stimulation
cardiovascular responses in congestive heart failure with cheyne- stokes respiration

Conditions: Heart Failure, Congestive; Cheyne-Stokes Respiration

Summary: the purpose of the trial is to investigate the cardiovascular response to peripheral chemoreceptor stimulation in congestive heart failure with cheyne- stokes respiration


Eligibility criteria:
inclusion criteria: * moderate to severe heart failure (nyha class ii or above) on optimal medical therapy * lvef less than or equal to 45% * stable condition as defined as no hospital admission or changes to medical therapy within two weeks prior to enrolment exclusion criteria: * patients taking known respiratory stimulants or depressants * clinically significant asthma requiring therapy * significant parenchymal lung disease * primary pulmonary hypertension * myocardial infarction within three months prior to enrolment * patients with cardiac resynchronisation devices and permanent pacemakers * anaemic (haemoglobin \< 12g/dl)
effects of talampanel on patients with advanced parkinson's disease

Conditions: Dyskinesias; Parkinson Disease; Movement Disorders

Summary: the purpose of this research study is to test the safety and effectiveness of the study drug, talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a result of treatment to parkinson's disease. it is not clear why people with parkinson's disease develop involuntary movements (dyskinesias) but studies show that blocking receptors in the brain for a chemical called glutamate decreases these movements. talampanel is a drug which blocks these receptors.


Eligibility criteria:
inclusion criteria: * troublesome on-period dyskinesias as defined by a unified parkinson's disease rating scale (updrs) dyskinesia sub-score \>25% of duration of dyskinesia during waking hours and 33 must have moderate disability * lang-fahn dyskinesia rating score more than 2 for at least two of the 5 tasks * must have dyskinesia on average 25% of waking hours/day based on patient diaries * have been diagnosed with parkinson's disease \> 5 years at screening exclusion criteria: * previous surgical therapies for pd * isolated or predominantly diphasic dyskinesias * moderate dementia * on disallowed concomitant medications including cyp3a4 inhibitors and inducers, amantadine, etc.

Keywords: involuntary movements abnormal movements advanced parkinson's disease levodopa induced dyskinesia
development of a canadian bronchiectasis and ntm database

Conditions: Bronchiectasis; Non-Tuberculous Mycobacterial Pneumonia

Summary: the investigators aim to develop a comprehensive patient registry of patients with non-cf bronchiectasis and/or nontuberculosis mycobacteria (ntm)

the investigators aim to develop a comprehensive patient registry of patients with non-cf bronchiectasis and/or nontuberculosis mycobacteria (ntm). this will entail inclusion of adults (age \>18 years) with a diagnosis of these conditions to be entered with complete clinical data and quality of life assessments entered into a patient registry.

Eligibility criteria:
inclusion criteria: * over the age of 18 * non-cf bronchiectasis * nontuberculosis mycobacteria (ntm) exclusion criteria: * under the age of 18 * cf bronchiectasis
bax 326 surgery study in hemophilia b patients

Conditions: Hemophilia B

Summary: the purpose of the study is to assess the hemostatic efficacy and safety of bax 326 in subjects with severe (fix level \< 1%) or moderately severe (fix level 1-2%) hemophilia b undergoing major or minor elective or emergency surgical, dental or other invasive procedures.


Eligibility criteria:
main inclusion criteria: * participant and/or legal representative has/have voluntarily provided signed informed consent. * participant has severe (fix level \< 1%) or moderately severe (fix level 1-2%) hemophilia b (based on the one stage activated partial thromboplastin time (aptt) assay), as tested at screening at the central laboratory. * participant requires surgery * participant has previously been treated with plasma-derived and/or recombinant fix concentrate(s) for a minimum of 150 exposure days * participant has no evidence of a history of fix inhibitors * participant is immunocompetent as evidenced by a cd4 count ≥ 200 cells/mm3. * participant is human immunodeficiency (hiv) negative or is hiv+ with a viral load \< 200 particles/μl \~ \< 400,000 copies/ml. main exclusion criteria: * participant has a history of fix inhibitors with a titer ≥ 0.6 bethesda units (bu) (as determined by the nijmegen modification of the bethesda assay or the assay employed in the respective local laboratory) at any time prior to screening. * participant has a detectable fix inhibitor at screening, with a titer ≥0.6 bethesda units (bu) as determined by the nijmegen modification of the bethesda assay in the central laboratory. * participant has a history of allergic reaction or evidence of an ongoing or recent thrombotic disease, fibrinolysis or disseminated intravascular coagulation (dic). * known hypersensitivity to hamster proteins or recombinant furin. * evidence of an ongoing or recent thrombotic disease, fibrinolysis or disseminated intravascular coagulation (dic). * abnormal renal function * severe chronic liver disease * active hepatic disease with alt or ast levels \> 5 times the upper limit of normal. * diagnosis of an iherited or acquired hemostatic defect other than hemophilia b. * platelet count \< 100,000/ml.
mri analysis of glycosaminoglycan modifications inside the intervertebral disk after distraction and posterior fusion

Conditions: Lumbar Spine Instability

Summary: degenerative disc disease (ddd) is the primary cause of low back pain. the most important factor in the development of ddd is the vertical load force on the disc, increasing the hydrostatic pressure and facilitating discs degenerations. one of the most common conditions accompanying ddd is segmental instability of the spine. the pathogenesis evolves in three phases characterized by a progressive disc dehydration and loss of the disc height. this phenomenon can be observed in magnetic resonance imaging (t2 weighted mri) as a decrease of the water signal inside the intervertebral disc. it is considered as an indirect sign of the alteration of the composition (including glycosaminoglycans) and the structure of the intervertebral disk with, as consequence, a modification of the spine biomechanics. animal studies showed that disc regeneration could be enhanced by a decrease of the hydrostatic pressure. this could be observed as a signal increase on t2 weighted mri. recent quantitative mri sequences now allow the quantification of glycosaminoglycans (gag) concentration inside the cartilage and in the intervertebral disc. the actual surgical trends are in favor of an anterior (intersomatic) vertebrak fusion, associated or not with a posterior fusion. these technics sacrifice the intervertebral disc and change the spine biomechanics. based on a pilot study, the investigators believe that the conservation and even a regeneration of the intervertebral disc is possible and allows the preservation of the spine biomechanics. the purpose of the study is to analyze the relations between specific mri signals, the gags concentration, and the functional outcome before and after the surgical treatment.


Eligibility criteria:
inclusion criteria: * patient with segmental instability of the lumbar spine * patient with planned surgery exclusion criteria: * clinical and iconographic signs of neurological compression * intervertebral disc completely degenerated * infection * spondylolisthesis (superior to grade i) * fracture * neoplasia.

Keywords: mri t2 weighted intervertebral disc glycosaminoglycans
heparin versus normal saline in peripherally inserted central catheter lines

Conditions: Cancer

Summary: the study team will be performing a study comparing the use of heparin flushes vs. normal saline flushes in making sure central lines stay open. the participants will be placed in a group to receive the university of texas southwestern medical center (utsw) standard of care (control group) for maintaining central lines, or a group to receive normal saline flushes only (experimental group) to keep their central line open. the participants electronic medical record will be reviewed by study team members for the inclusion/exclusion criteria, the participants central line will be assessed by an 11 blue bmt nurse every 12 hours, and they may be asked questions regarding their medical history during their stay on 11 blue bmt. if a participant is discharged or transferred off of the 11 blue bmt unit, they will no longer be included in the study and their central line maintenance will return to the utsw standard of care. participants in this study may be at risk for central line occlusion (a blood clot) which could require intervention to regain the free flow of fluids and use of the central line. the study team predicts there will be no increase in the rate of line occlusion when using normal saline flushes only to maintain the free flow of fluids through participants central line. the study team also hopes the results of this study will help to improve patient outcomes by decreasing risk of infection, heparin associated complications, and costs.


Eligibility criteria:
inclusion criteria: * oncology patients * admitted to 11blue bone marrow transplant unit at clements university hospital university of texas southwestern medical center * ages 18-80 years * pre-existing or newly placed picc line * picc line with good blood return (defined as: "brisk blood return of 3cc") * flushes without difficulty exclusion criteria: * patient less than 18 years of age or greater than 80 years of age * refused or unable to give consent to the study * patient admitted to the 11blue bmt unit with any line other than a picc line, or multiple lines * patient admitted to 11blue bmt for active transplant * patient with a coagulopathy diagnosis * patient on therapeutic dose of anticoagulants for documented deep vein thrombosis or pulmonary embolism * patient on inpatient hospice/comfort care * patient transferred off 11b bmt unit onto another floor

Keywords: peripherally inserted central lines heparin flush
18349-human photoallergy test

Conditions: Sunscreening Agents

Summary: to evaluate the potential of a test material to produce a photoallergic response.


Eligibility criteria:
inclusion criteria: * be male or female between the ages of 18 and 60 inclusive; * be lightly pigmented (fitzpatrick skin type i, ii, iii); * have read and signed the written informed consent form and have completed a health insurance portability and accountability act (hipaa) authorization form in conformance with 45cfr parts 160 and 164; * be in general good health as determined by the subject's medical history and in the discretion of the investigator; exclusion criteria: * have a visible sunburn; * have a history of sun hypersensitivity/photosensitivity or photosensitive dermatoses; * have a known hypersensitivity or allergy against any of the active and non-active ingredients of the investigational products. * subjects who are employees of the cro and/or bayer or is a household member of an employee
personalized computerized inhibitory control training for ocd

Conditions: Obsessive-Compulsive Disorder

Summary: this study will evaluate the effects of a computerized training program coupled with cognitive behavioral therapy (cbt) for ocd.

this study will evaluate the effectiveness of a computerized training program (called personalized computerized inhibitory training, or pcit) coupled with cognitive behavioral therapies (cbt) consisting of exposures and response prevention in treating obsessive compulsive disorder (ocd) in patients who previously underwent cbt, but still have residual symptoms.

Eligibility criteria:
inclusion criteria: * principal diagnosis of ocd (assessed by scid). * clinically significant ocd symptoms (y-bocs score of at least 16). * have a history of completing a trial of at least 1 ex/rp sessions. * have access to a computer or laptop. exclusion criteria: * individuals with the following disorders will excluded: bipolar, psychosis, current major depressive disorder (assessed by scid). * patients with head injury and loss of consciousness of more than five minutes or a neurological condition affecting the central nervous system. * patients taking a psychiatric medication will be asked to maintain a stable dose for 6 weeks prior to study entry. * vision or hearing loss (although individuals with vision corrected by glasses or contacts will not be excluded). * active suicidality warranting immediate clinical care.

Keywords: cognitive behavioral therapy
mind/body stress management to improve outcomes in workplace weight loss programs

Conditions: Obesity

Summary: the purpose of this study is to explore the efficacy of a phone-based weight loss program that has stress management techniques integrated throughout (weight talk-mindfulness). the program is targeted at employees of certain companies who meet a cut-off score on a measure of stress-related eating. the control group will receive a standard phone-based program with no additional stress management information (weight talk-standard). * hypothesis 1: participants in weight talk-mindfulness (wt-m; n=50) will experience decreases in their stress-related \& emotion-related eating compared to the weight talk-standard (wt-s; n=25) group. * hypothesis 2: the wt-m group will lose more weight compared to the wt-s control group. * hypothesis 3: participants in wt-m will experience decreased perceived stress, increased eating self-efficacy, increased acceptance of weight-related thoughts \& feelings and increased mindfulness compared to those in the wt-s control arm. * hypothesis 4: participants in wt-m will be equally as satisfied with their weight loss program as those in wt-s.


Eligibility criteria:
inclusion criteria: * be enrolled in the weight talk program, inclusion criteria: * employment by one of the employers who contract for weight talk services * being over 18 years of age * speak and read english * have a starting bmi between 25 and 35. * score 5 or higher on the 8-item internal disinhibition subscale of the eating inventory. * have regular access to email and internet. * willingness and ability to complete study and intervention procedures, including completing assessments, engaging in moderate physical activity (e.g., walking, swimming) and using the electronic scale at least once per week. exclusion criteria: * type 2 diabetes (type 1 is an exclusion for the weight talk program). * past diagnosis of anorexia nervosa or bulimia nervosa. * weight talk program exclusion criteria include: * pregnancy * bariatric surgery within past 12 months or planned in the next 6 months * undergoing dialysis * have type 1 diabetes diagnosis * women who are pregnant are not eligible for the program, but contraception is not required as this is a low risk study * currently using or planning to start using a pharmaceutical weight loss drug
cyclophosphamide added to standard immunosuppressive therapy with herombopag as front-line therapy in patients with severe aplastic anemia

Conditions: Severe Aplastic Anemia

Summary: this is a prospective, single-center, single-arm, phase 2 study. this study aims to evaluate the efficacy and safety of anti-lymphocyte globulin plus herombopag in combination with moderate-dose cyclophosphamide for severe aplastic anemia.


Eligibility criteria:
inclusion criteria: * male or female age ≥ 12 years * subject has a diagnosis of naïve severe or very severe aplastic anemia * ecog performance status ≤2 * unwilling or unable to receive allogeneic hematopoietic stem cell transplantation. * willing and able to comply with the requirements for this study and written informed consent. exclusion criteria: * previously received immunosuppressive therapy \> 4 weeks * previously treated with tpo-ra \> 4 weeks * have an allergy or intolerance to either herombopag or cyclophosphamide. * have an allergy to alg * uncontrolled systemic fungal, bacterial, or viral infection * poorly controlled hypertension (≥140/90mmhg) or diabetes (a fasting plasma glucose concentration ≥7.0mmol/l or a random venous plasma glucose concentration ≥11.1mmol/l) * abnormal liver or kidney function: alt or ast \>3 uln, or serum creatinine (scr)≥ 2.5 uln. * history of radiotherapy and chemotherapy for malignant solid tumors * combined with other serious disorders * pregnant or breast-feeding patients * patients considered to be ineligible for the study by the investigator for reasons other than the above.